AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28679554
Drug: Whey and
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey and calcium (whey+); 45-48 g/d
Trial: 28679554
Drug: Whey; 45-48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey; 45-48 g/d
Trial: 28679554
Drug: Soy; 45-48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy; 45-48 g/d
Trial: 28679554
Drug: Maltodextrin (control);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (control); 45-48 g/d
Trial: 1389521
Drug: CMF x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF x six (cyclophosphamide 100 mg/m2 orally on days 1‐14, methotrexate 40 mg/m2 intravenously on days 1 and 8, fluorouracil 600 mg/m2 intravenously on days 1 and 8 for six cycles)
Trial: 29338584
Drug: betaHB salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: betaHB salts (0.38 g kg body mass‐1) in plain water (3.8 mL kg body mass‐1)
Trial: 29338584
Drug: plain water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plain water (3.8 mL kg body mass‐1)
Trial: 22551127
Drug: Radioiodine dose
RxNorm normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine dose of 1.1 GBq
Trial: 22551127
Drug: Radioiodine dose
RxNorm normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine dose of 3.7 GBq
Trial: 22551127
Drug: Thyrotropin-stimulation method
RxNorm normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-stimulation method using thyroid hormone withdrawal
Trial: 22551127
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of radioiodine (1.1 GBq and 3.7 GBq)
Trial: 21265192
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac Sodium Sustained Release Tablets
Trial: 18206735
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g ethylic alcohol (149 ml of Gordon's Gin)
Trial: 18206735
Drug: 149 ml
RxNorm normalized name: anakinra 149 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 149 ml of water (placebo)
Trial: 8534699
Drug: Once-daily dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dose gentamicin (40 mg/2 L dialysate)
Trial: 8534699
Drug: Multiple-dose gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose gentamicin (10 mg/2 L dialysate administered 4 times per day)
Trial: 8534699
Drug: Once-daily dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dose gentamicin
Trial: 8534699
Drug: Multiple-dose gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose gentamicin
Trial: 6286517
Drug: Dexamethasone administration
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administration for 3 days prior to the test
Trial: 6286517
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 25 U of corticotropin 30 min pre-exercise
Trial: 15250431
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education and home physical therapy
Trial: 15250431
Drug: Education and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and physical therapy
Trial: 7865687
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH) 50 IU/kg i.v. with protamine sulphate (PS) 1 mg/100 IU of heparin
Trial: 7865687
Drug: Tinzaparin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin 50 anti-factor Xa IU/kg i.v. with PS 1 mg/100 IU of heparin
Trial: 7865687
Drug: Tinzaparin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin 75 anti-factor Xa IU/kg s.c. with PS 1 mg/100 IU of heparin
Trial: 7865687
Drug: Tinzaparin 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin 175 anti-factor Xa IU/kg s.c. with PS 1 mg/100 IU of heparin
Trial: 7865687
Drug: Saline s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline s.c. with PS 0.5 mg/kg
Trial: 31238591
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care group (n = 33)
Trial: 28844990
Drug: Pharmaco-invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaco-invasive strategy with half-dose alteplase
Trial: 23761205
Drug: W‐RENA (Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: W‐RENA (Internet-based maintenance treatment)
Trial: 17085994
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg tid PO
Trial: 15485403
Drug: Placebo-based conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-based conventional antihypertensive therapy
Trial: 11487451
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (conjugated estrogen with progestin)
Trial: 8204123
Drug: Accelerated tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated tissue plasminogen activator (t-PA) and intravenous heparin
Trial: 8204123
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of streptokinase plus t-PA with intravenous heparin
Trial: 8204123
Drug: Combination strategy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination strategy
Trial: 3732715
Drug: Diltiazem (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (360 mg daily)
Trial: 29669938
Drug: Canagliflozin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (300 mg/d)
Trial: 10774784
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment alone (matched controls with high cholesterol)
Trial: 10774784
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment alone (matched controls with normal cholesterol)
Trial: 1736002
Drug: Perfusion flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion flow rate at 1.75 L.min‐1.m‐2
Trial: 1736002
Drug: Perfusion flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion flow rate at 2.25 L.min‐1.m‐2
Trial: 30730957
Drug: TXA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA treatment
Trial: 30282686
Drug: Waiting-list group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list group (standard acupuncture treatment after the study)
Trial: 27100101
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 supplementation (90 μg) and cholecalciferol (10 μg)
Trial: 27100101
Drug: Cholecalciferol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (10 μg) alone
Trial: 25285539
Drug: Atazanavir, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir, 300 mg/d, with ritonavir, 100 mg/d
Trial: 25285539
Drug: Raltegravir, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir, 400 mg twice daily
Trial: 25285539
Drug: Darunavir, 800
RxNorm normalized name: Darunavir, 800 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir, 800 mg/d, with ritonavir, 100 mg/d
Trial: 22918156
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice daily for 24 weeks
Trial: 17388711
Drug: Galantamine (8-24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (8-24 mg)
Trial: 7549379
Drug: Astragalus membranaceus
RxNorm normalized name: Astragalus membranaceus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus membranaceus (AM) oral liquor combined with routine therapy
Trial: 26995369
Drug: hs-cTnT levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT levels <3 ng/L
Trial: 26995369
Drug: hs-cTnT levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT levels 3-14 ng/L
Trial: 26995369
Drug: hs-cTnT levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT levels ≥14 ng/L
Trial: 24033567
Drug: Walnut supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut supplement diet (75 g per day)
Trial: 22061077
Drug: Prucalopride (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride (2-4 mg daily)
Trial: 15548969
Drug: Cyclosporine withdrawal
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine withdrawal after 3 months of treatment with sirolimus
Trial: 15548969
Drug: Cyclosporine continued
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine continued after 3 months of treatment with sirolimus
Trial: 11578152
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily)
Trial: 29729555
Drug: Psychoeducation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation and Supportive Therapy (PST)
Trial: 25303337
Drug: Liberal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal paracetamol use
Trial: 25303337
Drug: Restricted paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted paracetamol use
Trial: 10438389
Drug: Intranasal mupirocin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin, twice daily for 5 days
Trial: 7551950
Drug: Cisplatin given
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin given daily with radiotherapy
Trial: 2350528
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg alone
Trial: 31762342
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) based pain education
Trial: 24293225
Drug: R&R2MHP cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R&R2MHP cognitive skills program (group treatment)
Trial: 24092567
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 μg) + Formoterol (6 μg) on demand
Trial: 24092567
Drug: Regular Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Regular Budesonide (400 μg) on demand
Trial: 24092567
Drug: Terbutaline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.5 mg) on demand
Trial: 11788109
Drug: Transvaginal natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvaginal natural progesterone gel (4% or 8%) applied every other day for six doses per month
Trial: 19181970
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg infusion)
Trial: 11600554
Drug: L-thyroxine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine (mean dose, 85.5 +/‐ 4.3 microg/d)
Trial: 10175988
Drug: Prolonged prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged prophylaxis with enoxaparin (low-molecular-weight heparin) administered during hospitalization and for 3 weeks after discharge
Trial: 10175988
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term prophylaxis administered only during hospitalization
Trial: 31752604
Drug: Strategy-based Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy-based Training to Enhance Memory (STEM) - 8-session treatment protocol incorporating self-generation, spaced learning, and retrieval practice.
Trial: 29668397
Drug: LED treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED treatment at 2.4 J/cm2 (wavelengths 625, 660, 850 nm) three times a week for 8 weeks
Trial: 25081363
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml foam (22 kcal) consumed immediately after main meals (M)
Trial: 25081363
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml foam (22 kcal) consumed after snacks (S)
Trial: 25081363
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml foam (22 kcal) consumed in-between snacks and main meals (I)
Trial: 9074306
Drug: Moclobemide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (mean dose 440 mg +/- 123 mg)
Trial: 9074306
Drug: Fluoxetine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (mean dose 35 mg +/- 8 mg)
Trial: 9074306
Drug: Fluoxetine (Control)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (Control)
Trial: 3021407
Drug: High-carbohydrate, guar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate, guar gum fiber (HCF) bars (35.7 g carbohydrate and 6.6 g guar gum/bar)
Trial: 27496046
Drug: Cognitive Patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Patient Education in combination with active individualized physiotherapy (COPE-PT)
Trial: 23716067
Drug: MTX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX plus hydroxychloroquine plus sulfasalazine plus low-dose prednisone (arm 1)
Trial: 23716067
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with MTX and prednisone
Trial: 19926503
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood injection into the superior joint space (SJS)
Trial: 19926503
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood injections to the SJS and the pericapsular tissues (PT)
Trial: 18539084
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (constant medication)
Trial: 10993127
Drug: Fluvoxamine (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50-100 mg/day)
Trial: 8959316
Drug: Regular NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular NSAID use (at least twice weekly for 12 months or longer)
Trial: 1388048
Drug: Fadrozole 1
RxNorm normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole 1 mg orally per day
Trial: 1388048
Drug: Fadrozole 4
RxNorm normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole 4 mg orally per day
Trial: 1388048
Drug: Fadrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole (1 or 4 mg)
Trial: 27322481
Drug: AERAS-422 high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AERAS-422 high dose (>10(6)‐<10(7)CFU)
Trial: 27322481
Drug: AERAS-422 low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AERAS-422 low dose (>10(5)‐<10(6)CFU)
Trial: 22834768
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks treatment with vaginal progesterone
Trial: 12118018
Drug: Concurrent thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent thoracic radiotherapy (TRT)
Trial: 12118018
Drug: Sequential thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential thoracic radiotherapy (TRT)
Trial: 7851354
Drug: Intrathecal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal infusion with a bolus dose of 100 micrograms morphine followed by a 24 h infusion of 200 micrograms morphine (8.3 micrograms h‐1)
Trial: 7851354
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion with a bolus dose of 2 mg of morphine followed by a 24 h infusion of morphine 200 micrograms h‐1 + 0.25% bupivacaine 4 ml h‐1
Trial: 2895963
Drug: HOE 760
RxNorm normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOE 760 (histamine H2-receptor antagonist)
Trial: 25418493
Drug: Ezetimibe 20
RxNorm normalized name: atorvastatin-ezetimibe 20 mg-10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 20 mg/d
Trial: 21645424
Drug: Self‐administered, semiquantitative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered, semiquantitative food frequency questionnaire (FFQ)
Trial: 16774480
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) - 24-hour intravenous infusion
Trial: 15322436
Drug: CEI of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEI of 0.5% bupivacaine plus IEB of 0.5% bupivacaine 4 times daily (n = 29)
Trial: 15322436
Drug: IEB of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IEB of normal saline plus IEB of 0.5% bupivacaine 4 times daily (n = 27)
Trial: 11771598
Drug: Target Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target Controlled Infusion (TCI) of propofol (3 to 8 microg/ml)
Trial: 11771598
Drug: Manually Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually Controlled Infusion (MCI) of propofol (approximately 2 mg/kg bolus and 3 to 10 mg/kg/h infusion)
Trial: 11771598
Drug: Target Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target Controlled Infusion (TCI) of propofol
Trial: 11771598
Drug: Manually Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually Controlled Infusion (MCI) of propofol
Trial: 8499957
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral conjugated equine estrogens, 0.625 mg daily, with sequential oral dl‐norgestrel, 0.15 mg daily, for 12 days per month
Trial: 8499957
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal estradiol‐17 beta, 0.05 mg daily, with sequential transdermal norethindrone acetate, 0.25 mg daily, for 14 days per month
Trial: 25257871
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 15 mg of terbutaline (TER)
Trial: 22486552
Drug: Pantoprazole treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole treatment for up to 16 weeks
Trial: 22486552
Drug: Observational phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observational phase after pantoprazole treatment
Trial: 17094978
Drug: Mifepristone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (25 mg, two pills every 14 days during DMPA therapy)
Trial: 17094978
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two pills every 14 days during DMPA therapy)
Trial: 17848882
Drug: 0.25 mL
RxNorm normalized name: mineral oil 0.25 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mL Epaxal
Trial: 17848882
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL Epaxal
Trial: 17848882
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection site pain
Trial: 9010709
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (0.05 mg.kg-1)
Trial: 6529913
Drug: Trazodone (223
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (223 mg daily)
Trial: 6529913
Drug: Amitriptyline (95.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (95.3 mg daily)
Trial: 21939467
Drug: DBS +
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DBS + Optimal Drug Therapy (ODT)
Trial: 9036412
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment according to the protocol of the German AML‐Cooperative Group (Münster, FRG)